NASDAQ:RANI Rani Therapeutics Q3 2026 Earnings Results & Report $0.55 -0.03 (-4.93%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Rani Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.04 versus the -$0.0475 consensus estimate, while revenue of $1.71 million topped the $1.28 million estimate by $427.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call DateNovember 9, 2026Conference Call4:00 PM ET Rani Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.0475Beat/MissBeat by +$0.0075One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersRani Therapeutics Revenue ResultsActual Revenue$1.71 millionExpected Revenue$1.28 millionBeat/MissBeat by +$427.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rani Therapeutics Q3 2026 Earnings FAQ Did Rani Therapeutics beat earnings estimates for Q3 2026? Rani Therapeutics (NASDAQ:RANI) reported earnings of -$0.04 per share for Q3 2026, beating the consensus estimate of -$0.0475. The report was announced on Tuesday, November 10, 2026. What was Rani Therapeutics' revenue for Q3 2026? Rani Therapeutics reported revenue of $1.71 million for Q3 2026, against a consensus estimate of $1.28 million. Rani Therapeutics Earnings HeadlinesRani Q3 Loss Widens On Higher R&D Expenses; RT-114 Phase 1a Expansion Data Due By Year-EndNovember 10 at 3:11 AM | rttnews.comRani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 3:11 AM | marketscreener.comMThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate UpdateNovember 9 at 4:05 PM | globenewswire.comRani Therapeutics (RANI) Expected to Release Earnings on ThursdayNovember 4, 2026 | americanbankingnews.comRani Therapeutics Holdings consensus price target decreased by 13.19% to $6.38October 23, 2026 | msn.comSee More Rani Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email. Email Address About Rani TherapeuticsRani Therapeutics (NASDAQ:RANI) is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion. The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies. Its development programs have included oral versions of therapies for conditions such as acromegaly and other chronic diseases. Rani Therapeutics has also pursued collaborations and partnerships to evaluate the platform with different biologic drug candidates. Rani Therapeutics was founded in 2012 and is headquartered in San Jose, California. The company became publicly traded in 2021. Its leadership includes Talat Imran, who serves as chief executive officer, while entrepreneur and medical-device inventor Mir Imran has been associated with the company as its founder and chairman.View Rani Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
